Initiation of coverage: The 'Clever' way to tackle MDS
Faron Pharmaceuticals is a Finnish biotech developing bexmarilimab (BEX), an immunotherapy in late stage development for the treatment of a rare type of hematologic cancer, high-risk myelodysplastic syndrome (HR-MDS). Encouraging phase 2 data supports a phase 3 trial starting H1 2026, targeting botFaron Pharmaceuticals is a privately owned clinical stage drug discovery and development company based in Finland. Co. has three major drug development projects focusing on: acute trauma; inflammatory diseases; and cancer growth and spread. Co.'s operations have been primarily focused on the development of its lead drug candidate, Traumakine®. Traumakine®, used to prevent vascular leakage and organ failures, is the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. Co.' second most advanced drug development project, Clevegen, revolves around Clever-1, a cell surface molecule involved in cancer growth and spread.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.